GH Research's stock rallied after saying the FDA lifted a hold on its experimental depression treatment The FDA lifted its hold on GH Research's psychedelic drug, sending the company's shares soaring.
Past performance is no guarantee of future results. Calculated for the Institutional Class based on a three-year period. Relative measures are compared with the fund’s benchmark. Portfolio holdings ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback